CAR T-Cell Therapy for Solid Tumors Improved by Custom Media Development

In cellular immunotherapies, such as CAR T-cells, clinical outcomes depend on the therapeutic product’s cytolytic potency and metabolic fitness. Generally, CAR T-cells are generated using standardized activation conditions. Then, they are expanded ex vivo for 9–14 days using media formulations that have not been optimized for gene delivery, cell expansion, or overall potency. Recent studies have shown that a newly developed serum replacement supports CAR T-cell expansion and function across a broad range of clinical and research-grade media. These findings inspired the creation of a new digital portal that simplifies decision making in medium configuration.

In this GEN webinar, our distinguished guest, Dr. Roddy O’Connor, will highlight many of these advances and share unique insights into optimizing media formulations for assessing potency during manufacturing and conditioning strategies to enhance metabolic fitness prior to adoptive transfer. Given the immediate challenge in extending the therapeutic value of CAR T-cells to solid tumors, defining parameters—as well as bioactive components that support CAR T cell quality and potency following infusion—has immediate translational relevance for the clinical sector.

A live Q&A session followed the presentation, offering you a chance to pose questions to our expert panelist.

Produced with support from: